Atara Biotherapeutics – Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder

Access Program Information

This is a multicenter expanded access protocol to provide human leukocyte antigen (HLA)
partially-matched third-party allogeneic EBV-CTLs for the treatment of EBV-associated
viremia and disease for which there is no comparable or satisfactory alternative therapy to
treat the patient’s disease or condition. Patients must not be eligible to enroll in
clinical trials designed to support the development and marketing approval of Atara

Rare Disease: